American Journal of Kidney Diseases 2003: Vol 42 Index

25 Pages·2003·5.7 MB·English

AUTHOR INDEX
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal
number, a colon, the letter E, and a number.
Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supple-
ment 3 (October 2003), Supplement 4 (November 2003), and Supplement 5
(December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.
Abbott, K.C., 1058 Baliga, S., 532 Burns, A., 582
Abe, K., 76 Ballanti, P., 1036 Burns, J.E., 1000
Abraham, M., 797 Bankhurst, A., 1212 Byers, P., 229, 1270
Abramson, F., 561 Barone, G.W., 202
Abul-Ezz, S.R., 202 Barré, P.E., 693 Cai, W., 532
Adachi, M., 1287 Bartlett, C., 551 Calabria, S., 1036
Calonge, V.M., 513
Adler, S.G., 395 Barz, A., 752
Agodoa, L.Y., 1058 Baumgarten, D.A., 601 Campbell, D.A. Jr., 151
Campbell, H., 3:E15
Aguilera, A., 787 Beck, G.J., 44
Ahuja, T.S., 376 Becker, B., 62 Carmody, S.S., 813
Carpenter, B., 1107
Akiba, T., 303 Becker, D.J., 117
Akioka, Y., 1121 Bedogna, V., 331 Carrie, B.J., 1020
Alhejaili, F., S1:24 Bendel, K.J., 3:xlviii Cass, A., 1043
Al-Hilali, N., 797 Bennett, W.M., 217 Castro, M.J., 787
Allen, A.S., 1260 Benoit, M.O., 513 Catalano, C., 722
Allon, M., 388, 612 Bergstralh, E.J., 685 Catania, A., 143
Al Mousawi, M., 797 Berns, J.S., 325 Cattran, D.C., 846
Al-Muzeirei, I.A., 797 Berto, I.M., 67 Caucci, F., 3:E11
Alpers, C.E., 605 + Cavallone, D., 658
Bhatacharia, K.F., 3:E17
Al-Shamari, A., 591 Bianchin, C., 1177 Cecka, J.M., 882
Amadori, F., 3:E1 | Bihorac, A., 704 Celadilla, O., 787
Ambiihl, P.M., 193 Cernelc, P., 746
Ammann, P., 193 BBilnaigkg,, YC..MR..,, 6S9t:31 Cetin, T., 1164
Anderson, P.W., 456 Chalermskulrat, W., 1149
André, J.-L., 5:E19 Blake, P.G., $1:42 Chan, L.Y-Y., 173
Andreoni, K., 5:E23 Bleyer, A.J., 2:E8 Chan, T.M., 173
Anger, M.S., 315 Blinder, J., 1:xlix Chang, C.-F., 3:E14
Ankenbrandt, M., 926 Block, G., 864 Chapman, A.B., 1305
Block, S.D., 813
Antignac, C., 1:E2 Charbonneau, P., 497
Boczula, M., 539
Appel, L.J., 256 Charest, A.F., 1193
Arakawa, H., 271 Boero, R., 67 Charney, D.A., 1097
Araki, S.-i., 943 Bonucci, E., 1036 Chen, C.-H., 990
Bosnyak, Z., 117
Arcidiacono, T., 1177 Chen, J.-Y., 3:E14
Arnold, R.M., 813 Bourgoignie, J.J., 1270, 1293 Chen, M.L.W., 623
Ars, E., 952 Bowden, D.W., 133 Chen, S.-C., 22
Ascher, N.L., 362 Brabant, G., 62 Chen, W.-T., 158
Ashizawa, M., 76 Brancaccio, D., 143 Chen, Y.-C., 586
Asif, A., 229, 1270, 1293 Brancati, F.L., 249, 256 Chertow, G.M., 217, 507
Avram, M.M., 864 Brayman, K., 1000 Cherubini, C., 546
Ayanian, J.Z., 1043 Bredi, E., 143 Chiang, H.W., 2:E6
Azzi, A., 821 Brémond-Gignac, D., 5:E19 Chikamoto, H., 1121
Brewster, P.S., 926 Chiu, Y.S., 2:E6
Badalamenti, S., 143 Briangon, S., 474 Cho, D.-K., 2:E7
Badenas, C., 952 Brophy, P.D., 1248 Cho, Y.-J., 2:E7
Bae, K., 2:E7 Brown, W.W., 22 Chow, K.-M., 5:xlviii, 567, 781
Baek, H.W., 6:E26 Buisson, C., 513 Chu, P., 1221
Bagga, A., 1114 Bulucu, F., 1164 Chua, B.S.Y., 1260
Baggio, E., 331 Bunchman, T.E., 1248 Chuang, F.-R., 524
Baines, L.S., 431 Buring, J.E., 234 Chung, J.-H., 6:E26
Bajo, M.A., 787 Burket, M.W., 926 Chvala, R., 315
Bakris, G.L., 617, 1301 Burkhart, J., 1082 Cigni, A., 3:E11
BalducciA,. , 1036 Burnett, S., 1184 Clark, W.F., S1:49
1334 American Journal of Kidney Diseases, Vol 42, No 6 (December), 2003: pp 1334-1357
AUTHOR INDEX
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal
number, a colon, the letter E, and a number.
Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supple-
ment 3 (October 2003), Supplement 4 (November 2003), and Supplement 5
(December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.
Abbott, K.C., 1058 Baliga, S., 532 Burns, A., 582
Abe, K., 76 Ballanti, P., 1036 Burns, J.E., 1000
Abraham, M., 797 Bankhurst, A., 1212 Byers, P., 229, 1270
Abramson, F., 561 Barone, G.W., 202
Abul-Ezz, S.R., 202 Barré, P.E., 693 Cai, W., 532
Adachi, M., 1287 Bartlett, C., 551 Calabria, S., 1036
Calonge, V.M., 513
Adler, S.G., 395 Barz, A., 752
Agodoa, L.Y., 1058 Baumgarten, D.A., 601 Campbell, D.A. Jr., 151
Campbell, H., 3:E15
Aguilera, A., 787 Beck, G.J., 44
Ahuja, T.S., 376 Becker, B., 62 Carmody, S.S., 813
Carpenter, B., 1107
Akiba, T., 303 Becker, D.J., 117
Akioka, Y., 1121 Bedogna, V., 331 Carrie, B.J., 1020
Alhejaili, F., S1:24 Bendel, K.J., 3:xlviii Cass, A., 1043
Al-Hilali, N., 797 Bennett, W.M., 217 Castro, M.J., 787
Allen, A.S., 1260 Benoit, M.O., 513 Catalano, C., 722
Allon, M., 388, 612 Bergstralh, E.J., 685 Catania, A., 143
Al Mousawi, M., 797 Berns, J.S., 325 Cattran, D.C., 846
Al-Muzeirei, I.A., 797 Berto, I.M., 67 Caucci, F., 3:E11
Alpers, C.E., 605 + Cavallone, D., 658
Bhatacharia, K.F., 3:E17
Al-Shamari, A., 591 Bianchin, C., 1177 Cecka, J.M., 882
Amadori, F., 3:E1 | Bihorac, A., 704 Celadilla, O., 787
Ambiihl, P.M., 193 Cernelc, P., 746
Ammann, P., 193 BBilnaigkg,, YC..MR..,, 6S9t:31 Cetin, T., 1164
Anderson, P.W., 456 Chalermskulrat, W., 1149
André, J.-L., 5:E19 Blake, P.G., $1:42 Chan, L.Y-Y., 173
Andreoni, K., 5:E23 Bleyer, A.J., 2:E8 Chan, T.M., 173
Anger, M.S., 315 Blinder, J., 1:xlix Chang, C.-F., 3:E14
Ankenbrandt, M., 926 Block, G., 864 Chapman, A.B., 1305
Block, S.D., 813
Antignac, C., 1:E2 Charbonneau, P., 497
Boczula, M., 539
Appel, L.J., 256 Charest, A.F., 1193
Arakawa, H., 271 Boero, R., 67 Charney, D.A., 1097
Araki, S.-i., 943 Bonucci, E., 1036 Chen, C.-H., 990
Bosnyak, Z., 117
Arcidiacono, T., 1177 Chen, J.-Y., 3:E14
Arnold, R.M., 813 Bourgoignie, J.J., 1270, 1293 Chen, M.L.W., 623
Ars, E., 952 Bowden, D.W., 133 Chen, S.-C., 22
Ascher, N.L., 362 Brabant, G., 62 Chen, W.-T., 158
Ashizawa, M., 76 Brancaccio, D., 143 Chen, Y.-C., 586
Asif, A., 229, 1270, 1293 Brancati, F.L., 249, 256 Chertow, G.M., 217, 507
Avram, M.M., 864 Brayman, K., 1000 Cherubini, C., 546
Ayanian, J.Z., 1043 Bredi, E., 143 Chiang, H.W., 2:E6
Azzi, A., 821 Brémond-Gignac, D., 5:E19 Chikamoto, H., 1121
Brewster, P.S., 926 Chiu, Y.S., 2:E6
Badalamenti, S., 143 Briangon, S., 474 Cho, D.-K., 2:E7
Badenas, C., 952 Brophy, P.D., 1248 Cho, Y.-J., 2:E7
Bae, K., 2:E7 Brown, W.W., 22 Chow, K.-M., 5:xlviii, 567, 781
Baek, H.W., 6:E26 Buisson, C., 513 Chu, P., 1221
Bagga, A., 1114 Bulucu, F., 1164 Chua, B.S.Y., 1260
Baggio, E., 331 Bunchman, T.E., 1248 Chuang, F.-R., 524
Baines, L.S., 431 Buring, J.E., 234 Chung, J.-H., 6:E26
Bajo, M.A., 787 Burket, M.W., 926 Chvala, R., 315
Bakris, G.L., 617, 1301 Burkhart, J., 1082 Cigni, A., 3:E11
BalducciA,. , 1036 Burnett, S., 1184 Clark, W.F., S1:49
1334 American Journal of Kidney Diseases, Vol 42, No 6 (December), 2003: pp 1334-1357
AUTHOR INDEX
Clement, L., $1:24, 56 Easow, S., 797 Garcia, J., 53, 264
Codoceo, R., 787 Easterling, T.R., 982 Garcia, P., 787
Coen, G., 1036 Ebben, J., 972 Garg, J., 1301
Cohen, L.M., 813 Ebben, J.P., 1013 Gaziano, J.M., 234
Cointault, O., 184 Eberhardt, M.S., 249, 256 Geier, P., 1107
Colamarco, L., 1036 Eknoyan, G., 617 Gerstein, H.C., 936
Colicigno, C.J., 133 Ellekjaer, H., 466 Ghaddar, S., 325
Colindres, R.E., 6:E25 El Menyawi, I., 310 Ghali, W.A., 125
Collins, A., 22 Elzinga, L., 315 Ghoneim, M.A., 370
Collins, A.J., 972, 1013, 1275 Emont, S.L., 713 Giaculli, F., 108
Colville, D., 2:E3 Endou, H., 1287 Giambona, S., 1177
Colyer, W.R., 926 Erlinger, T.P., 256 Gibney, E.M., |
Comandini, U.V., 546 Espinoza, M., 787 Gilbertson, D., 1275
Como, G., 143 Gillen, D.L., 982
Comoli, P., 821 Faedda, R., 3:E11 Ginevri, F., 821
Falk, R.J., 1149 Glynn, R.J., 234
Comoz, F., 4:E18
Farres, M.T., 1:E2 Goga, T., 2:E10
Contreras, G., 315
Cooper, C.J., 926 Feber,J. , 1107 Gohdes, D., 245
Fehr, T., 193 Goékden, N., 202
Coresh, J., 108, 256, 623
Feldman, H.I., 1000 Goldberg, T., 532
Counts, C., 12
Felicioni, R., 546 Goldfarb, D.S., |
Covini, G., 143
Feng, L., 575 Goldstein, M.B., 1193
Cozzupoli, P., 722
Ferguson, E., $1:56 Goodman, D.G., 207
Crikis, S., 207
Fernandez, J.S., 446 Gorban-Brennan, N., 350
Critchlow, C.W., 982
Ferrando, A., 1212 Gorry, M.C., 2:E8
Cunningham, J., 1043
Ferrario, F., 1154 Gotch, F., 167
Curioni, S., 1154 Filler, G., 1107 Gotoh, T., 5:E20
Cusi, D., 1177 Fink, N.E., 108 Graf, S., 62
Cutrupi, S., 722
Finkelstein, F.O., 350 Grand’ Maison, A., 1193
Finn, L.S., 1318 Grantham, J.J., 427
D’ Agati, V.D., 419 Finn, W.F., 96 Graziani, G., 143
Dahl, D., 1013 Firpo, M., 331 Greenbaum, L.A., 5:E22
D’ Amico, M., 1154 Fischer, M.S., 1036 Greene, T., 44, 1200
Danielski, M., 286 Flack, J.M., 22 Griffith, T.F., 1260
Danko, H., 713 Fliser, D., 62 Grénhagen-Riska, C., 1139
Fochesato, E., 1177 Groundstroem, K., 277
Danovitch, G.M., 882
Fogazzi, G.B., 1154 Griiter, E., 193
Darnell, A., 952
Fogo, A.B., 87, 2:xli, 826 Gurley, B.J., 202
DaRoza, G., 1184
Das, K.C., 797 Fontana, [., 821 Guymer, R., 2:E3
Franke, J., 936 Gyamlani, G.G., 685
Daubin, C., 497
Frankenfield, D.L., 806
Daugirdas, J.T., 1200
Franssila, K., 960 Haddad, E., 5:E19
Davies, D.R., 842
Frederick, P.R., 806 Hallan, H., 466
Davison, S.N., 1239
Freedman, B.I., 133 Haller, H., 62
Dedi, R., 3:E15
Freitas, T., 1020 Hamaoka, K., 5:E20
de Ligny, B.H., 4:E18
Friedman, E.A., 2:E4 Hamburger, R.J., 342
DeLong, M.J., 381
Frimat, L., 474 Haneda, M., 943
Depner, T.A., $1:42
Froio, N., 546 Harada, T., 76
de Santis, R., 821 Frye, R.F., 906 Hare, J.M., 891
Devins, G.M., 693
Fuchinoue, S., 739 Hari, P., 1114
Di Giulio, S., 546 Fuhrmann, V., 310 Hart, T.C., 2:E8
Ding, P.Y.-A., 990 Fujimoto, S.-i., 5:E20 Hartley, B., 3:E15
Di Zazzo, G., 1036 Fukazawa, A., 1121 Harwell, T.S., 245
Djurdjev, O., 1184 Fumeron, C., 513 Hattori, M., 1121
Dodd, M., 362 Funovics, M., 539 Hayashi, F., 3:E12
Dorman, J.S., 117 Furusu, A., 76 Hebert, L., 617
Dosekun, A.K., 3:E13 Hector, L., 362
Drey, N., 677 Gadalean, F., 1270 Heidenheim, A.P., S1:5, 24, 30, 36,
Drukker, A., 1107 Gadallah, M.F., 1270 42, 49, 56, 61
du Cheyron, D., 497 Gammaro, L., 331 Heinze, G., 539
Durand, D., 184 Gansevoort, R.T., 3:xIviii Heiro, M., 960
1336 AUTHOR INDEX
Helgerson, S.D., 245 Joffe, M., 1000 Koji, T., 76
Hemmelgarn, B.R., 125 Johnson, A., 561 Kolon, T., 1:xlix
Henke, D.C., 1149 Johnson, R.J., 575 Kopple, J.D., 761, 864
Henke, P., 151 Johny, K.V., 797 Kortas, C., $1:5, 13, 24, 61, 66
Hennekxens, C.H., 234 Jones, S.A., 752 Koskinen, P., 1139
Hibi, I., 295 Jordan, S.C., 1114 Kovarik, J., 539
Higami, Y., 1:E1 Joseph, J.T., 431 Kowalewska, J., 605
Hiki, ¥., 486 Joy, M.S., 96 Koya, D., 943
Hill, P,, 842 Kroeker, A., $1:49
Hill, P.A., 207 Kabaya, T., 303 Kuenzig, L., $1:49
Himmelfarb, J., 286, 507 Kaehny, W.D., 2:E5 Kumagai, H., 295
Hirakawa, S., 133 Kaizu, Y., 295 Kuo, S.-W., 774
Hishica, A., 2:E10, 3:E16 Kalantar-Zadeh, K., 761, 864 Kurella, M., 217
Ho, S.K.N., 173 Kamar, N., 184 Kuroki, A., 3:E12
Ho, Y.W., 5:E21 Kane, J.C., 286 Kurt, I., 1164
Hoenich, N.A., 167 Kanetake, H., 1:E1 Kurth, T., 234
Hogan, S.L., 1149 Kao, J.-T., 3:E14 Kusek, J.W., 44
Holley, J.L., 813 Kao, W.-Y., 158 Kvenild, K., 466
Holmen, J., 466 Karim, M., 842 Kwan, B.C.-H., 1069
Honkanen, E., 1139 Kashiwagi, A., 943
Hoofnagle, J.H., 631 Kato, A., 2:E10 Laboi, P., 3:E15
Hoogwerf, B.J., 936 Kato, M., 486 Lai, K.-B., 781
Horie. A., 486 Kausz, A.T., 972 Lai, K.N., 173
Horn, R.G., 87 Kawaguchi, H., 1121 Lanfranco, G., 67
Hosoyamada, M., 1287 Kawakatsu, H., 5:E20 Lange, E.M., 133
Hostetter, T., 617 Kawasaki, Y., 1131 Lapeyraque, A.-L., 5:E19
Hosteiter, T.H., 392 Kawashima, A., 303 Larson, T.S., 685
Houiltier, P., 497 Kayler, L.K., 151 Leavey, S., 151
Hsu, C.-y., 623 Kays, M.B., 342, 1253 Lecchi, P., 561
Hsu, 7.-L., 990 Kaysen, G., 167 Leclercq, B., 1270, 1293
Hsu, Y.-J., 774 Kaysen, G.A., 1200 Lee, G.H., 761
Huang, C.-C., 524 Keane, W.F., 22 Lee, J., 315
Huang, C.Y., 2:E6 Kempston, C., 1184 Lee, S., 1169
Huang, W.H., 158 Kennedy, D.J., 926 Lee, S.H., 6:E26
Huhtala, H., 277 Kessler, M., 474 Lee, T.W., 6:E26
Hung, Y.-J., 774 Kestenbaum, B., 982 Le Goas, F., 1:E2
Hurtado, A., 575 Khono, M., 1121 Lehn, R.S., 761
Hutchison, F., 12 Khuder, S.A., 926 Lehtimiki, T., 277
Kiaii, M., 1184 Leitch, R., $1:5. 24, 49, 56, 61
Ibrahim, H.N., 1275 Kielstein, J.T., 62 Lens, X., 952
Thm. C.G., 6:E26 Kim, M.J., 6:E26 Leskinen, Y., 277
Ikegaya, N., 295 Kim, Y.-L., 2:E7 Leung, C.-B., 567, 1069
Ikizler, T.A., 286, 507, 864 Kimmel, P.L., 713, 1200 Levey, A.S., 44, 108, 617, 623
Ilamathi, M.E., 419 King, K., 22 Levi, M., 2:E5
Iliou, M.C., 513 Kiser, R.L., 5:E23 Levin, A., 591, 1184
Inou, T., 729 Kissner, P.Z., 6:E24 Levin, N.W., 167, 1200
Irjala, K., 36 Kitamura, K., 1287 Lew, S.Q., 561
IshaniA,. , 1275 Kitazawa, K., 3:E12 Li, F.K., 173
Isoaho, R., 36 Kivela, S.-L., 36 Li, H.-Y., 586
Isomoto, H., 76 Kjellstrand, C., 1020 Li, P. K.-T., 567, 781, 1069
Isozaki, T., 3:E16 Klag, M.J., 22, 108 Li, P. K.T., 5:xI viii
Ito, K., 1121 Klarenbach, S., $1:18 Lien, Y.-H.H., 381
Itoh, K., 1287 Klassen, P.S., 1260 Lifrieri, F., 1036
Iwase, H., 486 Klemmer, P.J., 1149, 5:E23 Lin, C.-C., 3:E14, 586
lyoda, M., 3:E12 Kliger, A.S., 350 Lin, C.-L., 524
Izopet, J., 184 Knauss, J., 1000 Lin, S.-H., 586, 774, 1221
Kobayashi, Y., 271, 486 Lin, Y.-F., 158, 774
Jacob, L., 1:E2 Kog, M., 704 Lin, Y.-P., 990
Jacquot, C., 513 Kocar, I.H., 1164 Linas, S.L., 215
Jeon, K., 2:E7 Koga, S., 1:El Lindasy, R.M., S1:56
Jindal, R.M., 431 Kohno, S., 76 Lindley, E.J., 551
AUTHOR INDEX
Lindsay, R.M., 1:3, 5, 13, 18, 24, 30, McMonagle, E., 286 Nishimura, R., 117
36, 42, 49, 61, 66 Mehrabian, S., S1:66 Nissenson, A.R., 325, 761
Lipari, G., 331 Mehta, R.L., 507 Nitta, K., 303
Little, R.R., 245 Meier, P., 1:E2 Nofroni, I., 1036
Liu, P.-Y., 315 Mendelssohn, D.C., 693 Nolan, C.R., 1169
Lo, K.-Y., 1075 Menon, V., 44 Nolin, T.D., 906
Lo, W.K., 173 Merion, R.M., 151 Nonoguchi, H., 1287
Lobbedez, T., 4:E18 Merrill, D., 1270, 1293
Locatelli, F., 821, 1154 Merszei, J., 575 Oberbauer, R., 539
Loewen, A., 1184 Meyers, C.M., 631 Oda, H., 355
Loirat, C., 5:E19 Meyers, K., 1:xlix Odamaki, M., 295
Longenecker, J.C., 108 Meyette, M., S1:49 Odani, H., 486
Lonn, E.M., 936 Mig@éal, S.D., 6:E24 Oei, L.S., 2:E9
Lorenz, M., 539 Mignogna, G., 1177 Ogawa, Y., 729
Losurdo, G., 821 Mila, M., 952 Ogino, D., 1121
Love, J., 1184 Minagawa, T., 355 Oguz, Y., 1164
Lu, K.-C., 1221 Mishkin, G.J., 561 Ohashi, H., 355
Lu, M., 532 Mishkin, M., 561 Ohashi, N., 3:E16
Lucksiri, A., 342 Mitterbauer, C., 539 Ohkawa, S., 295
Luft, F.C., 1283 Mittermayer, C., 310 Ohkuma, T., 355
Lunghi, G., 143 Mix, T.-C. H., 972 Ohmit, S.E., 22
Lynes, L., 362 Miyaji, K., 295 Ohno, M., 355
Miyakawa, S., 1121 Ohtani, H., 1:E1
Maca, T., 539 Miyazaki, M., 76 Oksa, H., 1228
Maccario, R., 821 Moatti, N., 513 Oktenli, C., 1164
Macia, M., 53, 264 Moe, S.M., 1253 Olveira, A., 787
Maeda, K.. 486 Mohamed, N.A.-H., 370 O'Neill, W.C., 601
Maeda, S.. 943 Moist, L., 1:13, 18, 36 Ono, T., 5:E20
Maes, B., 4:xli Mollura, D.J., 891 Orchard, T.J., 117
Magil, A., 591 Molony, D.A., 22 Otsubo, O., 729
Magnasco, A., 752 Moore, G.M., 325 Ouwendyk, M., S1:56
Mak, S.-K., 1075 Mora, C., 53, 264 Overholser, B.R., 1253
Makiishi, T., 943 Morana, G., 331 Owen, W.F. Jr.., 806
Malagolini, N., 658 Morgan, D., $1:66 Ozgurtas, T., 1164
Manca, A., 3:E11 Morikawa, A., 271 Ozono, Y., 76
Mange, K.C., 1050 Morris, M.C., 431
Mann, J.F.E., 936 Morrow, J., 286 Paganini, E.P., 507
Manni, M., 1036 Moss, A.H., 713, 813 Paillard, M., 497
Manns, B.J., 125 Moudgil, A., 1114 Painter, P.L., 362
Mansueto, G., 331 Mougenot, B., 1:E2 Paiva, A.M., 787
Marcovina, S.M., 44, 108 Mueller, B.A., 342, 1253 Panescu, V., 474
Marcussen, N., 960 Muirhead, N., S1:18, 36, 49 Pangilinan, A., 167
Marino, C., 722 Mullee, M., 677 Park, S.-H., 2:E7
Markowitz, G.S., 419 Muros, M., 264 Parving, H.-H., 617
Mars, R.L., 315 Murphy, L., 167 Pascual, M.T., 507
Martin, J.L., 6:E25 Musabak, U., 1164 Pasquali, S., 1154
Martorano, C., 722 Pasternack, A., 1228
Marx, C., 1283 Nakakura, H., 1121 Pastorino, N., 821
Marx, M., 1283 Nakamura, M., 739 Patel, B., 1324
Maschio, G., 331 Nakashima, I., 486 Paueksakon, P., 87
Massara, C., 67 Nampoory, M.R.N., 797 Paul, S.M., 362
Matsunaga, A., 1121 Nasr, S.H., 419 Paulson, W.D., 752
Matsuo, M., 1:E1 Navarro, J.F., 53, 264 Penumalee, S., 6:E24
Matsushita, K., 1287 Nelson, R.G., 245 Peppa, M., 532
Mattila, K., 36 Nemeth, A.S., 926 Pereira, B.J.G., 972
Matzke, G.R., 906 Nesrallah, G., $1:13, 24 Perfumo, F., 821
Maxvold, N.J., 1248 Newmann, J.M., 713 Pergola, P.E., 1169
McAllister, C.J., 761 Nicastri, E., 546 Perosa, P., 67
McClellan, W.M., 806 Nigg, L., 193 Peters, K., $1:56
McDougall,J. , 1193 Nihei, H., 303 Peters, R.M., 22
McDowall, J.M., 245 Nishida, M., 5:E20 Petrosillo, N., 546
1338 AUTHOR INDEX
Ploin, P.-F., 851 Sabovic, M., 746 Shibata, T., 3:E12
Ploth, D.W., 12 Sadaniantz, A., 446 Shimokawa, I., 1:E1
Poggioli, J., 497 Sadaniantz, B.T., 446 Shinozaki, S., 2:E10
Poli, A., 331 Saed, T., 797 Shiraishi, I., 5:E20
Ponikvar, J.B., 746 Saha, H., 277 Sinclair, R.A., 2:E3
Ponticelli, C., 143 Sahani, M., 2:E9 Sintonen, H., 1228
Popovtzer, M.M., 2:E5 Sakai, H., 76 Skluzacek, P.A., 1169
Postorino, M., 722 Sakai, N., 1131 Slezak, J.M., 685
Powe, N.R., 108, 249, 256 Sakai, O., 3:E12 Smith, J.M., 1318
Pozzi, C., 1154 Sakiewicz, P., 325 Snelling, P., 1043
Pujo, M., 4:E18 Salant, D.J., 395 Sobh, M.A.-K., 370
Pulliam, J., 315 Salobir, B., 746 Soldati, L., 1177
Pupim, L., 286 SalonenT,. , 1228 Solmone, M., 546
Salusky, I.B., 5:E19 Soro, G., 3:E11
Salvadori, M., 143 Soroko, S., 507
Quan, H., 125 Sanchez, S., 787 Sowinski, K.M., 342,
Quarello, F., 67 Sandhu, J., 2:E8 Spanner, E., $1:30
Quattrocchio, G., 1154 Sandres-Saune, K., 184 St. Peter, W. L., 972
Sanisoglu, S.Y., 1164 Stampfer, M.J., 234
Rabb, H., 599, 891 Santacroce, S., 167 Stassen, P.M., 3:xlviii
Raj, D.S.C., 1212 Santopietro, A., 821 States, L., 1:xlix
Ram, S.J., 752 Sardella, D., 1036 Steffes, M.W., 617
Ramakers, M., 497 Sarnak, M.J., 44, 596 Stehman-Breen, C.O., 631, 982
Ramakumar, S., 381 Satta, A.E., 3:E11] Sugarman, J.R., 806
Savage, B.R., 507 Sugathan, T.N., 797
Rao, M., $1:18
Savige, J., 2:E3 Sugisaki, T., 3:E12
Rashkow, A., 936
Schenk, P., 310 Sugiura, T., 3:E16
Ratheiser, K., 310
Ray, K., 362 Schlaeper, C., $1:66 Sullivan, A.M., 813
Schleicher, R.B., 325 Suri, R., $1:13, 30, 42
Reddan, D.N., 1260
Schmitt, D., 381 Suzuki, H., 1131
Refaie, A.F., 370
Schneditz, D., 167 Suzuki,J ., 1131
Reif, M.S., 1149
Schnuelle, P., 385 Suzuki, M., 271
Reina, T., 1228
Schulman, G.W., 1200 Swamy, S., 752
Renaudineau, E., 4:E18
Schwartz, S.M., 982 Symons, J.M., 1318
Renner, E.L., 193
Schwarz, C., 539 Szezech, L.A., 1260
Revelo, M.P., 87 Scott, K.M., 381 Szeto, C.-C., 567, 781, 1069
Rexrode, K.M., 234
Scott, M.K., 34? Szeto, C.Y.-K., 781
Reynolds, J.C., 1058
Scudo, P., 722 Szewc, R.G., 1169
Rianthavorn, P., 5:E19
Seeff, L.B.. 631:
Ribes, D., 184 Segagni, S, 1154 Taber, T.E., 315
Rich, S.S., 133 Segal, J.H., 151 Tajima, N., 117
Richardson, D., 551
Segal, M.S., 704 Takada, N., 355
Riehle, H.-M., 193 Selgas, R., 787 Takahashi, H.E., 729
Riley, D.J., 1169
Seliger, S.L., 982 Takahashi, M., 486
Rizk, D., 1305 Seligman, P.A., 325 Takizawa, T., 271
Robert, N., 315 Selves, J., 184 Tam, M.K., 5:E21
Roberts, I.S.D., 842 Sementa, A., 821 Tanaka, M., 1287
Roderick, P., 677 Serafini-Cessi, F., 658 Tanda, F., 3:E11
Rodriguez-Iturbe, B., 575 Serna, J.H., 3:E13 Tang, A.W.C., 5:E21
Rogerson, M., 677 Sethi, S., 2:E9 Tang, S., 5:E21
Rollino, C., 67, 1154 Shafritz, R., 315 Tanji, M., 1131
Romundstad, S., 466 Shah, H., 1212 Tarver-Carr, M.E., 249, 256
Ronco, C., 167 Shah, V.O., 1212 Taylor, C.M., 5:E19
Ronco, P., 1:E2 Shapiro, J.1., 926 Tayior, J.G.C., 2:E5
Rosas, S.E., 1000 Shappell, S., 87 Taylor, P., 591
Rostaing, L., 184 Sheashaa, A., 370 Taylor, P.A., 1184
Roth, D., 229, 1270, 1293 Sheerin, N.S., 3:E17 Tedla, F.M., 2:E4
Rubinacci, A., 1177 Shemin, D., 315 Teitelbaum, I., 1082
Ruutu, M., 1139 Shepp, P.H., 12 Teppo, A.-M., 1139
Ryan, H., $1:49 Sherif, A.M., 370 Teraoka, S., 739
Ryckelynck, J.-P., 4:E18 Shiao, M.-S., 3:E14 Terranegra, A., 1177
SUBJECT INDEX
Tessitore, N., 331 van Poelgeest, B.E., 3:xIviii Wuerth, D.B., 350
Textor, S.C., 858 Vanrenterghem, Y., 4:xli
Thalhammer, F., 310 van Willebrand, E., 1139 Xue, J., 972
Thomas, D., 6:E25 Vassalotti, J.A., 532 Xue, J.L., 1013
Thomas, D.B., 5:E23 Vega, B. T., 952
Thomas, W.J., 926 Vesely, T., 315 Yajima, A., 729
Thompson, B., 582 Vezzoli, G., 1177 Yamamoto, T., 3:E16
Ting, G.O., 1020 Vieira, C.F., 229, 1270 Yan, G., 1200
Tokuyama, K., 271 Virtanen, V., 277 Yan, H.-C., 158
Yang, A.-H., 3:E14, 586
Tomford, R.C., 605 Vlassara, H., 532
Tominaga, Y., 729 Yang, C.-W., 524
Yang, H.-Y., 524
Tomita, K., 1287
Wakita, N., 1287 Yang, W.-C., 3:E14, 586, 990
Tomlanovich, S.L., 362
Tong, G.M.W., 1075 Walker, A.M., 234 Yasuda, Y., 486
Wang, A.Y.-M., 1069
Tornroth, T., 960, 1139 Yenicesu, M., 1164
Wang, X., 44 Yeung, K., 591
Torra, R., 952
Toth, H.L., 5:E22 Wanger, A., 3:E13 Yeung, L.-K., 1221
Warnock, D.G., 388 Yi, Q.-L., 936
Toto, R., 617
Toto, R.D., 1200 Wasén, E., 36 Yildiz, O., 1164
Wasser, W., 1097 Yoo, T.-H., 6:E26
Trachtman, H., 2:E8
Troidle, L., 350 Watanabe, J.-i., 1:El Yoon, K.S., 6:E26
Tsai, T.J., 2:E6 Watnick, S., 350 Young, E., 1107
Tuppin, P., 513 Watt, C.-L., 1075 Yu, C.-C., 524
Turney, J.H., 3:E15 Webb, M.C., 3:E17 Yu, F.-C., 158
Tuttle, K.R., 456 Weiner, D.E., 596 Yu, W.-C., 990
Welch, R., $1:49 Yuan, C.M., 1058
Weng, F.L., 1050 Yumura, W., 303
Uchida, K., 303 White, S., S1:49 Yusuf, S., 936
Urata, Y., 5:E20 Will, E.J., 551
Uribarri, J., 532 Winearls, C.G., 842 Zager, P.G., 1212
Wolfe, R., 1212 Zarghamee, S., 102
Vagelli, G., 67 Wong, A.K.M., i075 Zhu, F., 167
Vahlberg, T., 36 Wong, P.-N., 1075 Zoccali, C., 722
van Baarlen, J., 3:xlviii Wong, T.Y.-H., 567, 781 Zsom, L., 752
Vandermarliere, A., 4:xli Wong, Y., 1075 Zupan, I.P., 746
van der Woude, F.J., 385 Woo, J.C.Y., 173 Zwillich, C.W., 2:E5
SUBJECT INDEX
Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal
number, a colon, the letter E, and a number.
Page references to Supplement 1 (July 2003), Supplement 2 (July 2003), Supple-
ment 3 (October 2003), Supplement 4 (November 2003), and Supplement 5
(December 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.
Access, vascular. See Vascular access kidney function changes in healthy men and, 234-244
Access to care N-Acetyl-b-glucosaminidase excretion in type 2 diabetes,
kidney transplantation, late referral to nephrologist and, pentoxifylline effects on, 264-270
1043-1049 Acidosis r)
socioeconomic status and, 249-255 caused by starvation and stress, 5:E22 j
Accreditation Counsel for Graduate Medical Education, metabolic, $3: 129-130 |
core nephrology curriculum and, 215-216 Acquired reactive perforating collagenosis, allopurinol
ACE inhibitors. See Angiotensin-converting enzyme inhibi- therapy for nondiabetic HD patient, 3:E12
tors ACR. See Albumin-creatinine ratio
Acetaminophen Acute coronary syndromes, antithrombotic agents for renal
in end-stage renal disease, 217-228 patients and, 446-455
1340 SUBJECT INDEX
Acute renal failure (ARF) Allergic disease, interleukin-4-related gene polymorphisms
after retrograde pyelography, 2:E6 and, 271-276
cohort study, reasons for nonenrollment in, 507-512 Allocation algorithm development, for kidney transplanta-
early, novel urinary markers for, 599-600 tion, 882-890
exercise-induced, with familial renal hypouricemia, Allograft, renal
1287-1292 dysfunction, dense deposit disease and, 207-211
in renal lymphoma, diagnosis by percutaneous kidney bi- HBV and HCV-infected, evaluation of, 193-201
opsy, 960-97 1 loss, in BKV-associated interstitial nephritis, retransplan-
tubule injury, NHE3 as marker for, 497-506 tation after, 821-825
Acute tubular necrosis, NHE3 protein as marker for, 497— mortality in elderly ESRD patients and, 1013-1019
506 multicentric papillary renal carcinoma in, 381-384
Adequacy preexisting crescentic glomerulonephritis in, 5:E23
of peritoneal dialysis, 1082-1096 survival, residual renal function in preemptive kidney
of quotidian hemodialysis, S1:42—48 transplantation and, 1275-1282
ADPKD (autosomal dominant polycystic kidney disease), Allopurinol, for acquired reactive perforating collagenosis
nephrology core curriculum, 1305-1317 in nondiabetic HD patient, 3:E12
Adrenocorticotropic hormone deficiency, presenting with Alport’s syndrome
hypercalcemia, 2:E10 nephrology core curriculum, 1305-1317
Adult-onset tubulointerstitial nephritis and uveitis, with sac- retransplantation after polyoma BK virus-associated allo-
roileitis and EBV infection, 3:E11 graft loss, 821-825
Advanced glycation end products (AGEs) Aluminum, overload and toxicity in CKD
circulating in renal failure, dietary glycotoxins and, 532- clinical features and therapeutic considerations, $3:108-
538 116
reduction by on-line hemodialfiltration in long-term he-
treatment algorithm, S3:116—122
modialysis, 524-531
Amino acids
Adynamic bone disease, K/DOQI Clinical Practice Guide-
in CAPD dialysate, long-term study of, 173-183
lines, $3:125-127
in ESRD hemodialysis patients, 1212-1220
African Americans
Amphotericin B, for mucormycosis peritonitis during long-
HIV-positive male, immunotactoid glomerulopathy in,
term PD, 3:E13
6:E25
Amyloidosis, long-term outcome of kidney transplant, 370-
matrix metalloproteinase 9 gene in ESRD, 133-142
375
receipt of renal replacement therapy and, 249-255
Analgesic usage
Age
in ESRD, 217-228
chronic kidney disease risk and, $4:34-S4:41
kidney function changes in healthy men and, 234-244
prognosis for LCDD with renal involvement, 1154-1163
for pain in hemodialysis, 1239-1247
thrombotic microangiopathy after renal transplantation
renal disease in postphenacetin era and, 385-387
and, 1058-1068
ANCA-positive glomerulonephritis
AGEs. See Advanced glycation end products
associated with minocycline, E9
AKRIB1 C-106T polymorphism, in diabetic nephropathy,
recurrence after kidney transplantation, 4:E18
943-95 |
Alarms, for nocturnal hemodialysis monitoring, $1:61-65 Anderson-Fabry disease, nephrology core curriculum,
Albumin, serum 1305-1317
correlation with enPCR and CRP, 1200-1211 Anemia
CRP levels chronic kidney disease and, 44-52 in chronic kidney disease, KEEP program participants
hypoalbuminemia and, S4:49-S4:56
heme iron polypeptide in HD patients, 325-330
chronic kidney disease and, 256-263
inflammation and oxidative stress in maintenance HD, malnutrition-inflammation complex syndrome in dialysis
286-294 and, 864-88 |
quality of life in ESRD and, 713-721 management in quotidian hemodialysis, $1:18—23
in quotidian hemodialysis, $1:30-35 renal tubular dysfunction in B-thalassemia minor, 1164—
Albumin, urinary. See Microalbuminuria 1168
Albumin-creatinine ratio (ACR) Angiotensin-converting enzyme (ACE) inhibitors
health status of elderly and, 36-43 for atherosclerotic renal artery stenosis, 851-857
in microalbuminuria testing, 245-248 with calcium channel blockers for nondiabetic nephropa-
Albumin to osmolality ratio, in predicting 24-hour urine al- thy, 67-75
bumin excretion in diabetes mellitus, 685-692 for cardiovascular risk reduction in dialysis patients,
Albuminuria. See Microalbuminuria 1301-1304
Aldose reductase, in Japanese patients with type 2 diabetes, progression of renal insufficiency in type 2 diabetes mel-
943-95 | litus, 936-942
Alkalosis, metabolic hypochloremic, efter small bowel Animal models of diabetic nephropathy, ruboxistaurin ef-
transplant rejection-related diarrhea, 1283-1286 fects in, 456-465
SUBJECT INDEX 1341
Annexin-V expression, in ESRD hemodialysis patients, with renal artery stenosis, medical management of, 851—
1212-1220 857, 858-863
Anterior ischemic optic neuropathy, in pediatric chronic state of endothelium in hemodialysis, circulating endothe-
peritoneal dialysis, 5:E19 lial cells and, 704-712
Antibody titer, natural hepatitis B immunity in long-term Atopy, interleukin-4-related gene polymorphisms and, 271—
HD patients, 1193-1199 276
Anticoagulant Citrate Dextrose Solution Formula A with Atypical pneumonia, severe acute respiratory syndrome in
Normocarb, for pediatric CVVH, 1248-1252 hemodialysis patient, 1069-1074
Anticonvulsants, in end-stage renal disease, 217-228 Autologous stem cell transplantation, for LCDD with renal
Antidepressants, in end-stage renal disease, 217-228 involvement, 1154-1163
Anti-glomerular basement membrane nephritis Autosomal dominant polycystic kidney disease (ADPKD),
dual pattern of immunofluorescence positivity, 419-426 nephrology core curriculum, 1305-1317
with periglomerular granulomatous reaction and eosino- Autosomal recessive Alport’s syndrome, as collagen type IV
philic infiltration, 3:E16 disease, 952-959
Antihypertensive drugs Autosomal recessive polycystic kidney disease (ARPKD),
for hypertension treatment in incident HD and PD, 1260- nephrology core curriculum, 1305-1317
1269 AVF. See Arteriovenous fistula
utilization to reduce cardiovascular risk in dialysis pa-
tients, 1301-1304 BCAAs (branched-chain amino acids), in ESRD hemodialy-
Antineutrophil cytoplasmic antibodies, plasmapheresis for sis patients, 1212-1220
small-vessel vasculitis diffuse alveolar hemorrhage, BCKAD (branched-chain keto acid dehydrogenase), hemo-
1149-1153 dialysis effects on, 1212-1220
Antiplatelet drugs, for acute coronary syndromes in renal Benign familial hematuria, as collagen type IV disease, 952—
patients, 446-455 959
Antithrombotic agents, for acute coronary syndromes in re- Beta-blockers
nal patients, 446-455 for hypertension treatment in incident HD and PD, 1260-
Aortic atherosclerosis, in chronic renal failure, 277—285 1269
Apheresis utilization to reduce cardiovascular risk in dialysis pa-
for diffuse alveolar hemorrhage in small-vessel vasculitis, tients, 1301-1304
1149-1153 Bicarbonate, albumin and creatinine serum levels in dialysis
LDL, for children with — steroid-resistant FSGS, patients and, 1200-1211 ;
1121-1130 Bicarbonate replacement fluid, and citrate anticoagulation
triple- vs. dual-lumen catheters for, 315-324 for pediatric CV VH, 1248--1252
Apolipoprotein(a), atherosclerotic cardiovascular disease in Bioavailability of ciprofloxacin, effects of calcium acetate
dialysis patients and, 108-116 and sevelamer on, 1253-1259
Apolipoprotein E3/3, in protein glomerulopathy with psoria- Bioimpedance spectroscopy, of large-artery structure and
sis vulgaris, 3:E14 function in HD, 990-999
Apoptosis, in ESRD hemodialysis patients, 1212-1220 Bisphosphonate, PTH secretion in postmenopausal HD
ARF. See Acute renal failure patients with secondary hyperparathyroidism, 122i-
ARPKD (autosomal recessive polycystic kidney disease), 1227
nephrology core curriculum, 1305-1317 Blindness, anterior ischemic optic neuropathy in pediatric
Arteriosclerosis CPD, 5:E19
large-artery, ECF-ICF ratio in HD patients and, 990-999 Blood loss, anemia management in quotidian HD patients
progression of renal insufficiency in type 2 diabetes mel- and, $1:18—23
litus, 936-942 Blood pressure
Arteriovenous fistula (AVF) anterior ischemic optic neuropathy in pediatric CPD,
creation by nephrologists, 1293-1300 5:E19
stenosis detection and thrombosis prediction, 331-341 chronic kidney disease risk and, $4:34—S4:41
successful maturation, predictors of, 1000-1012 elevation. See Hypertension
transposed basilic vein, vascular outcome and, 151-157 quotidian hemodialysis and, $1:13—17
Ascorbic acid supplementation, effect on oxidative stress targeted kidney disease screening and, 22—35
parameters in HD, 158-166 Blood vessel prosthesis, in vivo validation of glucose pump
Aspirin test for access flow, 752-760
for acute coronary syndromes in renal patients, 446-455 BMD (bone mineral density), intestinal calcium absorption
kidney function changes in healthy men and, 234-244 in hypercalciuric stone-forming women and,
: Atherosclerosis 1177-1183
carotid, in PD patients, 355-361 Body mass index (BMI)
in CRF, transesophageal echocardiography of, 277-285 chronic kidney disease risk and, $4:34-S4:41
in end-state renal disease, lipoprotein(a) and, 108—116 health status of elderly, cystatin C and, 36-43
malnutrition-inflammation complex syndrome in dialysis KEEP program participants, $4: 16-27, S4:28-33
and, 864-88 1 quotidian hemodialysis and, $1:30-35
1342 SUBJECT INDEX
in renal transplant recipients, exercise training effects on, Cardiovascular disease
362-369 circulating AGEs in renal failure, dietary giycotoxins and,
serum leptin in renal osteodystrophy and, 1036-1042 532-538
targeted kidney disease screening and, 22-35 CRP levels chronic kidney disease and, 44-52
Bone disease in dialysis patients, lipoprotein(a) and, 108-116
adynamic, $3:125-127 in ESRD
assessment in chronic kidney disease, $3:57—62 lipoprotein(a) and, 108-116
in chronic kidney disease, $3:29-44 prognostic value of cardiac markers for, 513-523
in kidney transplant recipient, $3:130-140 hypertensive pregnancy and, 982-989
Bone histomorphometry, serum leptin in renal osteodystro- malnutrition-inflammation complex syndrome in dialysis
phy and, 1036-1042 and, 864-881
Bone marrow stem cells, for renal disease, 891-905 microalbuminuria as risk marker for, 596-598
Bone marrow transplantation, renal tubular regeneration by microalbuminuria testing methods in, 245-248
bone marrow-derived cells after, 5:E20 progression of renal insufficiency in type 2 diabetes mel-
Bone mineral density (BMD), intestinal calcium absorption litus, 936-942
in hypercalciuric stone-forming women and, risk factors
1177-1183 in renal transplant patients, exercise training effects on,
Bone remodeling, after parathyroidectomy for secondary 362-369
hyperparathyroidism, 729-738 vascular calcification in long-term HD and, 303-309
Booster vaccination, natural hepatitis B immunity in long- special studies, $5:141—150
term HD patients, 1193-1199 state of endothelium in HD, circulating endothelial cells
Bowel perforation, from peritoneoscopic PD catheter inser- and, 704-712
tion, 1270-1274 Carotid atherosclerosis, in PD patients, 355-361
Brain injury, starvation ketoacidosis and, 5:E22 Case mix, adapting Charlson Comorbidity Index for ESRD,
Branched-chain amino acids (BCAAs), in ESRD hemodi- 125-132
alysis patients, 1212-1220 Cast nephropathy, Tamm-Horsfall glycoprotein and,
Branched-chain keto acid dehydrogenase (BCKAD), hemo- 658-676
dialysis effects on, 1212-1220 Catheter-related infections, triple- vs. dual-lumen catheters
and, 315-324
Cadaver kidney allocation, algorithm development for, 882— Catheters
890 insertion, in diagnostic and interventional nephrology pro-
Calcineurin inhibitors, thrombotic microangiopathy after re- gram, 229-233
nal transplantation and, 1058-1068 mortality in elderly ESRD patients and, 1013-1019
Calcium peritoneal dialysis, 1082-1096
adrenocorticotropic hormone deficiency in long-term HD triple- vs. dual-lumen for hemodialysis and apheresis,
and, 2:E10 315-324
hypocalcemia, in chronic kidney disease, $3:29-44 CD68, prognosis of MPGN type I renal dysfunction and,
intestinal absorption in idiopathic hypercalciuria, BMD in 1131-1138
stone-forming women and, 1177-1183 Cell-mediated immunity, effect of hygiene and socioeco-
lanthanum carbonate effects on, 96-107 nomic factors on, 575-581
metabolism, evaluation of, $3:52—57 Cellulose acetate high performance-210 hemodialyzer, levo-
pamidronate for secondary hyperparathyroidism and, floxacin removal, 342-349
1221-1227 CHANCE (Chronic Hemodialysis and New Cardiac Mark-
quotidian hemodialysis and, $1:24-29 ers Evaluation), prognostic value of cardiac markers
Calcium acetate and sevelamer, bioavailability of cipro- in ESRD, 513-523
floxacin and, 1253-1259 Charlson Comorbidity Index, adapting for use in ESRD,
Calcium carbonate, vascular calcification in long-term HD 125-132
and, 303-309 Chemotherapy, for LCCD with renal involvement,
Calcium-channel blockers 1154-1163
with ACE inhibitor, for nondiabetic nephropathy, 67-75 Children
for hypertension treatment in incident HD and peritoneal on CPD, anterior ischemic optic neuropathy in, 5:E19
dialysis, 1260-1269 CVVH with Normocarb replacement fluid and citrate an-
Calcium oxalate, nephrolithiasis in cystic fibrosis and, |-11 ticoagulation, 1248-1252
Calcium-phosphorus product, K/DOQI Clinical Practice in-center hemodialysis, ESRD Clinical Performance Mea-
Guidelines, $3:77-84 sures Project 2002 Annual Report on, $2:48-56
Calcium X phosphate, quotidian hemodialysis and, S1: with minimal change nephrotic syndrome, IL-4 gene
24-29 polymorphisms in, 271-276
Cannulation, in quotidian hemodialysis, $1:56—60 MPGN type I renal dysfunction prognosis, a-smooth
CAPD. See Continuous ambulatory peritoneal dialysis muscle actin and, 1131-1138
Capsase-3, in ESRD hemodialysis patients, 1212-1220 renal transplant recipients, quality of life for, 431-445